Evidence map›Paper›PMID 39331307›Full record

ArticleEmergency radiology2024

Amyloid related imaging abnormalities in the emergency setting.

Jan Czerminski, Supriya Khatri, Balaji Rao

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Emergency radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jan Czerminski *Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.
Supriya Khatri *Queen's University School of Medicine, Kingston, ON, Canada.
Balaji RaoDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA. Balaji.Rao@yale.edu.ORCID http://orcid.org/0000-0001-9945-1300

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the 2021 FDA approval of the first monoclonal antibody (MAB) therapy for Alzheimer's disease (AD), treatment has progressed from symptom management to targeting and reducing amyloid β plaque burden. While these therapies offer hope of altering the disease course, they come with risks, such as amyloid-related imaging abnormalities (ARIA), which include ARIA-E (edema and effusion) and ARIA-H (hemorrhage). This report details the case of a 64-year-old woman undergoing donanemab treatment who developed severe ARIA, characterized by extensive vasogenic edema and multiple microhemorrhages. The increasing use of MABs necessitates heightened awareness and expertise among emergency radiologists to identify findings of ARIA effectively, ensuring timely and appropriate care for patients undergoing these novel therapies.

Indexed as

Alzheimer DiseaseBrain EdemaDiagnosis, DifferentialEmergency Service, HospitalFemaleHumansMagnetic Resonance ImagingMiddle AgedTomography, X-Ray ComputedAlzheimer's diseaseAmyloid-related imaging abnormalitiesARIAARIA-EARIA-H

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.